Synaptic Transmission and Neural Integration Study Guide

Fundamentals of Synapses

• Definition: A synapse is a specialized junction between two neurons that facilitates communication. Synapses are classified into chemical synapses and electrical synapses.

• Chemical Synapses:

  • The most common type of synapse in the nervous system.

  • Operates unidirectionally, passing signals exclusively from the presynaptic neuron to the postsynaptic neuron.

  • The presynaptic neuron synthesizes, stores, and releases chemical messengers called neurotransmitters (NTs).

  • Neurotransmitters cross the synaptic cleft and bind to specific receptors on the postsynaptic cell membrane.

  • Key structural components of chemical synapses:

  • Presynaptic Axon Terminal: Terminal extension of the presynaptic axon containing mitochondria for ATP generation and membrane-bound synaptic vesicles.

  • Synaptic Vesicles: Membrane-enclosed sacs filled with thousands of neurotransmitter molecules.

  • Active Zone / Vesicle Docking Site: Specialized presynaptic membrane regions where vesicles dock and undergo exocytosis.

  • Synaptic Cleft: Fluid-filled extracellular space separating the presynaptic and postsynaptic membranes.

  • Postsynaptic Density: Protein-dense region of the postsynaptic membrane containing neurotransmitter receptors.

• Electrical Synapses:

  • Plasma membranes of the presynaptic and postsynaptic neurons are directly connected via channel structures called gap junctions.

  • Allows ionic electrical current to flow directly and rapidly between cells.

  • Electrical transmission is fast and can operate bidirectionally.

• Functional Classifications:

  • Excitatory Synapses: Increase the probability of an action potential in the postsynaptic cell.

  • Inhibitory Synapses: Decrease the probability of an action potential or stabilize the membrane potential in the postsynaptic cell.

Anatomical Types and Neuronal Network Patterns

• Anatomical Classifications of Neuron-to-Neuron Synapses:

  • Axodendritic Synapse: Axon terminal of a presynaptic neuron forms a synapse with a dendrite of a postsynaptic neuron.

  • Axosomatic Synapse: Axon terminal of a presynaptic neuron forms a synapse directly with the cell body (soma) of a postsynaptic neuron.

  • Axoaxonic Synapse: Axon terminal of one neuron forms a synapse with the axon terminal of another neuron, functioning primarily in presynaptic modulation.

• Arrangement Patterns in Neuronal Networks:

  • Convergence: Multiple presynaptic neurons synapse onto a single postsynaptic neuron, allowing the postsynaptic cell to integrate signals from diverse sources.

  • Divergence: A single presynaptic neuron branches out to synapse onto multiple postsynaptic neurons, allowing a single signal to spread to multiple downstream cells.

Mechanisms of Neurotransmitter Release

• Sequential Steps of Presynaptic Neurotransmitter Exocytosis:

  1. An action potential propagates down the presynaptic axon and arrives at the axon terminal.

  2. Depolarization of the axon terminal triggers the opening of voltage-gated $\text{Ca}^{2+}$ channels in the terminal membrane.

  3. Calcium ions ($\text{Ca}^{2+}$) enter the axon terminal rapidly, moving down their steep electrochemical gradient.

  4. Influx of $\text{Ca}^{2+}$ binds to specific proteins, triggering synaptic vesicles docked at the active zone to fuse with the plasma membrane and release neurotransmitters into the synaptic cleft via exocytosis.

  5. Released neurotransmitter molecules diffuse across the synaptic cleft and bind to specific receptors on the postsynaptic membrane.

  6. Neurotransmitter molecules are subsequently cleared from the synaptic cleft to conclude the chemical signal.

Signal Termination Mechanisms

• Reversibility of Neurotransmitter Binding: Binding of a neurotransmitter to a postsynaptic receptor is transient and non-covalent.

• Clearance Pathways for Unbound Neurotransmitters:

  • Active Reuptake: Transport proteins actively pump intact neurotransmitter molecules back into the presynaptic terminal for repackaging or destruction.

  • Glial Cell Uptake & Degradation: Astrocytes and other glial cells surround the synapse, taking up neurotransmitters to metabolize or degrade them.

  • Passive Diffusion: Neurotransmitter molecules diffuse out of the synaptic cleft into the surrounding interstitial fluid.

  • Enzymatic Degradation: Specialized enzymes located in the synaptic cleft break down neurotransmitter molecules into inactive metabolites.

• Pharmacological Application: Selective Serotonin Reuptake Inhibitors (SSRIs) block presynaptic reuptake transporters for serotonin, extending the duration of action for serotonin within the synaptic cleft.

Signal Transduction Mechanisms: Ionotropic vs. Metabotropic Receptors

• Postsynaptic Potential (PSP): A graded electrical potential change in the postsynaptic membrane resulting from neurotransmitter-receptor interaction.

• Ionotropic Receptors (Fast Responses):

  • The receptor unit is itself a ligand-gated ion channel.

  • Binding of neurotransmitters directly induces a conformational change that opens or closes the ion channel.

  • Produces rapid onset and short-duration postsynaptic potentials.

• Metabotropic Receptors (Slow Responses):

  • The receptor and ion channel are physically separate membrane proteins coupled via G-proteins ($\alpha$, $\beta$, and $\gamma$ subunits).

  • Direct G-Protein-Gated Channel Pathway:

  1. Neurotransmitter binds to the metabotropic receptor.

  2. G-protein is activated, causing the $\alpha$ subunit to dissociate.

  3. The $\alpha$ subunit moves along the inner membrane to directly open or close an adjacent ion channel.

• G-Protein-Coupled Second Messenger System:

  1. Neurotransmitter (first messenger) binds to the metabotropic receptor.

  2. G-protein is activated.

  3. Activated G-protein subunit interacts with an effector enzyme to activate or inhibit it.

  4. Effector enzyme catalyzes the production or degradation of a second messenger (e.g., cAMP).

  5. Second messenger opens or closes ion channels indirectly or triggers downstream intracellular responses.

Excitatory Chemical Synapses and EPSPs

• Excitatory Postsynaptic Potential (EPSP):

  • A depolarizing graded potential that shifts the postsynaptic membrane potential ($V_m$) closer to the threshold required to trigger an action potential (e.g., moving from $-70\,\text{mV}$ toward threshold).

• Ionic Mechanism of Fast EPSPs:

  • Neurotransmitter binding opens non-specific cation channels permeable to both $\text{Na}^+$ and $\text{K}^+$.

  • Simultaneously, $\text{Na}^+$ flows rapidly into the cytosol (driven by strong electrochemical force) while $\text{K}^+$ flows slowly out of the cytosol (driven by a weaker electrochemical force).

  • The net influx of positive charge causes membrane depolarization.

• Primary Central Neurotransmitter: Glutamate is the most prevalent excitatory neurotransmitter in the Central Nervous System (CNS).

Inhibitory Chemical Synapses and IPSPs

• Inhibitory Postsynaptic Potential (IPSP):

  • A graded potential change that hyperpolarizes the postsynaptic membrane (making $V_m$ more negative than resting potential, e.g., below $-70\,\text{mV}$) or stabilizes membrane potential at resting level to prevent depolarization.

  • IPSPs occur exclusively in the Central Nervous System (CNS).

• Ionic Mechanisms of IPSPs:

  • Potassium Channel Opening: Outward efflux of $\text{K}^+$ leaves net negative charge inside the membrane, causing hyperpolarization.

• Chloride Channel Opening Dynamics (3 Scenarios):

  • Scenario (a) Active Transport Out of Cell: Primary active transport uses ATP to pump $\text{Cl}^-$ out of the cell, establishing a steep inward concentration gradient. Opening $\text{Cl}^-$ channels causes influx of negative $\text{Cl}^-$ ions, producing a hyperpolarizing IPSP.

  • Scenario (b) No Active Transport (Equilibrium): $\text{Cl}^-$ is not actively pumped, causing $\text{Cl}^-$ equilibrium potential to match resting $V_m$. Opening $\text{Cl}^-$ channels produces no net $\text{Cl}^-$ flux, stabilizing $V_m$ at resting potential.

  • Scenario (c) Concurrent Excitatory Input: $\text{Cl}^-$ is at equilibrium, but both an excitatory synapse (opening cation channels) and an inhibitory synapse (opening $\text{Cl}^-$ channels) fire together. Inflowing $\text{Cl}^-$ cancels out inflowing cation positive charges, neutralizing depolarization and stabilizing $V_m$.

• Primary Central Neurotransmitter: Gamma-aminobutyric acid (GABA) is the most common inhibitory neurotransmitter in the CNS.

Neural Integration and Summation

• Principle of Neural Integration:

  • The membrane potential ($V_m$) at the axon hillock represents the mathematical integration of all EPSPs and IPSPs acting on the neuron simultaneously.

  • If net depolarization at the axon hillock reaches threshold (e.g., $-55\,\text{mV}$), an action potential is generated.

• Types of Summation:

  • Temporal Summation: Occurs when a single presynaptic neuron fires multiple action potentials in high-frequency succession. The resulting EPSPs overlap before previous ones decay, adding together to reach threshold.

  • Spatial Summation: Occurs when multiple distinct presynaptic neurons fire action potentials simultaneously at different dendritic/somatic locations. The individual EPSPs combine spatially across the membrane to reach threshold.

  • Excitatory and Inhibitory Cancellation: Simultaneous activation of an excitatory synapse and an inhibitory synapse causes the negative charge from the IPSP to neutralize the positive charge from the EPSP, maintaining $V_m$ below threshold.

Synaptic Strength and Presynaptic Modulation

• Factors Governing Synaptic Strength:

  • Stronger initial stimuli generate suprathreshold graded potentials, firing action potentials at a higher frequency along the axon.

  • Higher action potential frequency at presynaptic terminals leads to prolonged opening of voltage-gated $\text{Ca}^{2+}$ channels and greater $\text{Ca}^{2+}$ entry.

  • Increased intracellular $\text{Ca}^{2+}$ triggers exocytosis of more neurotransmitter vesicles.

  • Higher neurotransmitter concentration in the cleft increases postsynaptic receptor occupancy, inducing larger EPSPs or IPSPs in the postsynaptic neuron.

  • EPSPs and IPSPs occur primarily at axodendritic and axosomatic synapses.

• Presynaptic Modulation via Axo-axonic Synapses:

  • Axo-axonic synapses selectively modulate neurotransmitter release from a target presynaptic terminal without altering overall responsiveness across the entire postsynaptic cell body.

  • Autoreceptors on presynaptic terminals bind the neuron's own released neurotransmitter to provide self-regulatory negative feedback.

• Mechanisms of Presynaptic Modulation:

  • Presynaptic Facilitation: An axo-axonic modulating neuron increases $\text{Ca}^{2+}$ entry into the target terminal upon activation, resulting in greater neurotransmitter release and enhanced EPSP generation in the postsynaptic cell.

  • Presynaptic Inhibition: An axo-axonic modulating neuron suppresses $\text{Ca}^{2+}$ influx in the target terminal, decreasing neurotransmitter release and reducing the resulting postsynaptic response.

Major Neurotransmitter Systems

• Acetylcholine (ACh):

  • Synthesis: Synthesized from acetyl CoA and choline within presynaptic axon terminals.

  • Localization: Major neurotransmitter of the Peripheral Nervous System (PNS); released by cholinergic neurons.

  • Cholinergic Receptors:

  • Nicotinic Cholinergic Receptors: Fast ionotropic receptors that directly open cation channels ($\text{Na}^+$ influx, $\text{K}^+$ efflux).

  • Muscarinic Cholinergic Receptors: Slow metabotropic receptors coupled to G-proteins that activate enzymes, second messengers, or ion channels.

  • Inactivation: Degraded in the synaptic cleft by Acetylcholinesterase (AChE).

• Biogenic Amines:

  • Derived from amino acid precursors and synthesized within axon terminals.

  • Catecholamines (Derived from Tyrosine):

  • Dopamine: Acts as a key "feel good" neurotransmitter in reward pathways.

  • Norepinephrine: Released by adrenergic neurons; acts on adrenergic receptors.

  • Epinephrine: Released by adrenergic neurons and adrenal medulla; acts on adrenergic receptors.

  • Serotonin: Derived from tryptophan; functions as a critical mood enhancer.

  • Histamine: Derived from histidine; functions as a central neurotransmitter and key mediator of inflammatory responses.

• Amino Acid Neurotransmitters:

  • Represent the most prevalent class of neurotransmitters within the CNS.

  • Glutamate: Primary excitatory neurotransmitter in the CNS; opens $\text{Na}^+$ and $\text{Ca}^{2+}$ channels to generate EPSPs.

  • Glycine: Major inhibitory neurotransmitter in the spinal cord.

  • GABA (gamma-aminobutyric acid): Primary inhibitory neurotransmitter in the CNS; opens $\text{Cl}^-$ channels to generate IPSPs.

  • Clinical Pharmacology: Pharmaceuticals such as Valium, Xanax, and various sedatives bind to GABA receptor complexes to enhance inhibitory neuroconduction and depress overall brain electrical activity. Combining these agents with alcohol is hazardous due to synergistic central nervous system depression.

• Neuropeptides (Peptides):

  • Chains of amino acids constituting the largest structural class of neurotransmitters.

  • Examples:

  • Endogenous Opioids: Enkephalins and Endorphins (mediate analgesia and euphoria).

  • Thyrotropin-Releasing Hormone (TRH).

  • Antidiuretic Hormone (Vasopressin).

  • Oxytocin.

  • Substance P: Mediates pain transmission pathways.

  • Orexin: Regulates sleep-wake architecture and promotes wakefulness.

• Gases, Purines, and Lipids:

  • Nitric Oxide (NO): A gas that diffuses freely through membranes without binding membrane surface receptors; acts as a potent smooth muscle relaxant.

  • Purines: ATP, ADP, and Adenosine; serve signaling roles in both the CNS and PNS.

  • Lipids: Synthesized from cell membrane phospholipids and arachidonic acid.

  • Prostaglandins.

  • Thromboxanes.

  • Leukotrienes.

  • Endocannabinoids: Endogenous lipid messengers that bind to cannabinoid receptors (Tetrahydrocannabinol / THC, the primary active ingredient in marijuana, binds directly to these same cannabinoid receptors).

Pharmacological, Clinical, and Pathological Synaptic Modifications

• Receptor Desensitization: Decreased responsiveness of postsynaptic receptors following continuous or high-concentration agonist exposure.

• Pharmacological Ligands:

  • Agonists: Molecules that bind to receptors and activate them, mimicking endogenous neurotransmitter action.

  • Antagonists: Ligands that bind to receptors without activating them, competitively blocking natural neurotransmitter binding.

• Toxins and Pharmacological Agents:

  • Botulism Toxin: Inhibits vesicle exocytosis, preventing acetylcholine release at presynaptic terminals.

  • Curare: Competitive antagonist that blocks nicotinic acetylcholine receptors, preventing muscle contractions and causing paralysis.

  • Local Anesthetics (Novocaine and Lidocaine): Block fast voltage-gated $\text{Na}^+$ channels along neuronal cell membranes, stopping action potential generation and propagation to prevent pain transmission.

• Pathological Conditions:

  • Myasthenia Gravis: Autoimmune disorder characterized by autoantibodies that target and destroy postsynaptic nicotinic acetylcholine receptor sites, causing severe, progressive skeletal muscle weakness.